BioCryst Pharmaceuticals, Inc. provided earnings guidance for the full year 2022. For the period, the company expected full year 2022 net ORLADEYO revenue to be between $255 million and $265 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.515 USD | +5.93% | +2.29% | +8.10% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.10% | 1.27B | |
+8.04% | 114B | |
+9.83% | 104B | |
-1.83% | 22.57B | |
-9.81% | 22.5B | |
-10.39% | 17.95B | |
-41.90% | 16.48B | |
-13.86% | 15.82B | |
+3.04% | 13.55B | |
+29.34% | 10.99B |
- Stock Market
- Equities
- BCRX Stock
- News BioCryst Pharmaceuticals, Inc.
- Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022